Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Grade Last Price % Change Price Change
grade A 8.63 1.41% 0.12
ADAP closed up 1.41 percent on Friday, February 16, 2018, on 70 percent of normal volume.
1 Watcher
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Up Up Up
See historical ADAP trend table...

Date Alert Name Type % Chg
Feb 16 Wide Bands Range Expansion 0.00%
Feb 16 Up 3 Days in a Row Strength 0.00%
Feb 16 Up 4 Days in a Row Strength 0.00%
Feb 16 Up 5 Days in a Row Strength 0.00%
Feb 15 Wide Bands Range Expansion 1.41%
Feb 15 Up 3 Days in a Row Strength 1.41%
Feb 15 Up 4 Days in a Row Strength 1.41%
Feb 14 50 DMA Support Bullish 4.86%
Feb 14 New Uptrend Bullish 4.86%
Feb 14 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 4.86%

Older signals for ADAP ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Is ADAP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 3 bullish, 0 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.705
52 Week Low 3.88
Average Volume 427,147
200-Day Moving Average 6.7914
50-Day Moving Average 7.9431
20-Day Moving Average 8.6125
10-Day Moving Average 8.33
Average True Range 0.5397
ADX 24.45
+DI 26.46
-DI 18.12
Chandelier Exit (Long, 3 ATRs ) 8.0859
Chandelier Exit (Short, 3 ATRs ) 9.0791
Upper Bollinger Band 9.4231
Lower Bollinger Band 7.8019
Percent B (%b) 0.51
BandWidth 18.823803
MACD Line 0.0799
MACD Signal Line 0.1304
MACD Histogram -0.0505
Fundamentals Value
Market Cap 807.07 Million
Num Shares 93.5 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -8.72
Price-to-Sales 39.39
Price-to-Book 2.97
PEG Ratio 0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.32
Resistance 3 (R3) 9.30 9.04 9.21
Resistance 2 (R2) 9.04 8.87 9.06 9.17
Resistance 1 (R1) 8.84 8.76 8.94 8.86 9.13
Pivot Point 8.58 8.58 8.64 8.60 8.58
Support 1 (S1) 8.38 8.41 8.48 8.40 8.13
Support 2 (S2) 8.12 8.30 8.14 8.09
Support 3 (S3) 7.92 8.12 8.06
Support 4 (S4) 7.94